Year in Review: Updates in Treating Myelofibrosis - Episode 8

Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

,

Drs Rampal and Kuykendall highlight the benefits of pacritinib for patients with low platelet counts, as evidenced by the PERSIST-2 study, and momelotinib for patients with anemia, as shown in the MOMENTUM Phase 3 Study, focusing on their efficacy in spleen volume reduction and symptom relief in patients with myelofibrosis.